3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Pancreatic Neoplasms
2
Colorectal Neoplasms
1
Advanced Cancer
1
Interventions
Nivolumab
11
Ipilimumab
6
linrodostat
4
relatlimab
3
Pemetrexed
2
tislelizumab
1
regorafenib
1
ralimetinib
1
p38 Mitogen-Activated Protein Kinases
1
mirdametinib
1
gedatolisib
1
figitumumab
1
efatutazone
1
abemaciclib
1
Vorinostat
1
Tetanus Toxoid
1
Tamoxifen
1
Sunitinib
1
Ranitidine
1
Midazolam
1
LY2603618
1
LY2584702
1
Irinotecan
1
Gemcitabine
1
Fulvestrant
1
Dasatinib
1
Cyclophosphamide
1
Crizotinib
1
Cetuximab
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Advanced Cancer
×
BMS-813160
×
Clear all
NCT02996110
2022-12-19
FRACTION-RCC
Bristol-Myers Squibb
Phase 2
Completed
182 enrolled
23 charts